The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis

Atherosclerosis

Volumn 125, Issue 2, 1996, Pages 217-229

  Regnström, Jan ^a   Walldius, Göran ^a   Nilsson, Sven ^b   Schäfer Elinder, Liselotte ^c   Johansson, Jan ^a   Mölgaard, Jörgen ^d   Holme, Ingar ^e   Olsson, Anders G ^d   Nilsson, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cholestyramine; High density lipoprotein; Human atherosclerosis; Lipid soluble vitamins; Low density lipoprotein; Oxidation; Probucol; Quantitative arteriography

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; COLESTYRAMINE; COPPER ION; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYCOPENE; PROBUCOL; RETINOL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEMORAL ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; LIPID PEROXIDATION; MACROPHAGE ACTIVATION; MALE; PRIORITY JOURNAL; PROTEIN MODIFICATION; QUANTITATIVE DIAGNOSIS;

EID: 0030572773     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05880-7     Document Type: Article

References (57)

1. [1] Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915.
2. [2] Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biological modified low density lipoprotein. Arteriosclerosis 1983;3:149.
3. [3] Hessler J, Morel D, Lewis L, Chisholm G. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 1983;3:215.
4. [4] Quinn MT, Parthasarathy S, Fong LG, Steiberg D. Oxidatively modified low density lipoprotein: a potential role in recruitment and retention of monocytes/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995.
5. [5] Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U 937. Proc Natl Acad Sci USA 1990;87:904.
6. [6] Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928.
7. [7] Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effects of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic (WHHL) rabbit. Proc Natl Acad Sei USA 1987;84:7725.
8. [8] Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444.
9. [9] Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett W. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450.
10. [10] Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T. Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 1983;48:157.
11. [11] Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986;57:29H.
12. [12] Buckley M, Goa K, Price A, Brogden R. Probucol A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drugs 1989;37:762.
13. [13] Walldius G, Erikson U, Olsson A, Bergstrand L, Hådell K, Johansson J, Kaijser L, Lassvik C, Mölgaard J, Nilsson S, Schäfer-Elinder L, Stenport G, Holme I. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875.
14. [14] Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Mölgaard J, Nilsson S, Stenport G, Kaijser L, Lassvik C, Holme I. Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): A status report. Am J Cardiol 1988;62:37B.
15. [15] Lowry O, Rosenbrough N, Farr A, Randall R. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265.
16. [16] McFarlane AS. Labelling of plasma proteins with radioactive iodine. Biochem J 1956;62:135.
17. [17] Yagi K. Short communications. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976;15:212.
18. [18] Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 1975;6:307.
19. [19] Thyberg J, Nilsson J, Hellgren D. Recirculation of cationized ferritin in cultured mouse peritoneal macrophages. Electron microscopic and cytochemical studies with double-labeling technique. Eur J Cell Biol 1980;23:85.
20. [20] Regnström J, Walldius G, Carlson LA, Nilsson J. Effect of probucol treatment on oxidation of low density lipoprotein isolated from hypercholesterolemic patients. Atherosclerosis 1990;82:43.
21. [21] Regnström J, Walldius G, Hådell K, Johansson J, Holme I, Olsson A, Nilsson J. Influence of lipoprotein lipids, dietary fat and smoking on macrophage degradation of native and oxidized low density lipoprotein. Atherosclerosis 1994;110:13.
22. [22] Esterbauer H, Striegl G, Puhl H, Rothender M. Continous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 1989;6:67.
23. [23] Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183.
24. [24] Carlson K. Lipoprotein fractionation. J Clin Pathol 1973;5:32.
25. [25] Zlatkis A, Zak B, Boyle AJ. A new method for the direct determination of serum cholesterol. J Lab Clin Med 1953;41:486.
26. [26] Fletcher MJ. A colorimetric method for estimating serum triglycerides. Clin Chim Acta 1968;22:393.
27. [27] Schäfer Elinder L, Walldius G. Simultaneous measurement of serum probucol and lipid-soluble antioxidants. J Lipid Res 1992;33:131.
28. [28] Schäfer Elinder L, Hådell K, Johansson J, Mölgaard J, Olsson A, Walldius G. Serum lipid-soluble antioxidants in patients with hyperlipoproteinemia. Nutr Metab Cardiovasc Dis 1994;4:197.
29. [29] Schäfer Elinder L, Hådell K, Johansson J, Mölgaard J, Holme I, Olsson A, Walldius G. Probucol treatment decreases serum concentrations of diet-derived antioxidants. Arterioscler Thromb Vasc Biol 1995;15:1057.
30. [30] Nilsson S, Erikson U. Changes in atheroma volume estimated from digitized femoral arteriograms. Acta Radiol 1990;31:249.
31. 2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscl Thromb Vasc Biol 1995;15:1049.
32. [32] Parthasarathy S, Barnett J, Fong L, High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275.
33. [33] Mackness M, Durrington P. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243.
34. [34] Bowry V, Stanley K, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992;89:10316.
35. [35] Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoprotein. Nature (London) 1990;344:160.
36. [36] Frostegård J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified low density lipoprotein increases the adhesive properties of endothelial cells. Atherosclerosis 1991;90:119.
37. [37] Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981;78:6499.
38. [38] Stiko-Rahm A, Hultgårdh-Nilsson A, Regnström J, Hamsten A, Nilsson J. Oxidized and native LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human arterial smooth muscle cells. Arterioscler Thromb 1992;12:1099.
39. [39] Ardlie N, Selley M, Simons L. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989;76:117.
40. [40] Drake T, Hannani K, Frei H, Lavi S, Berliner J. Minimally modified oxidized LDL induces tissue factor expression in cultured human endothelial cells. Am J Pathol 1991;138:601.
41. [41] Latron Y, Chautan M, Anfosso F, Alessi M, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991;11:1821.
42. [42] Bocan T, Mueller S, Quenby Brown E, Uhlendorf P, Mazur M, Newton R. Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand While Rabbits. Exp Mol Pathol 1992;57:70.
43. [43] Daugherty A, Zweifel B, Schonfeld G. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. Br J Pharmacol 1991;103:1013.
44. [44] The alpha-tocopherol, beta carotene cancer prevention study group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029.
45. [45] Jialal I, Norkus E, Cristol L, Grundy S. Beta-carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1991;1086:134.
46. [46] Princen H, van Poppel G, Vogelzang C, Buytenhek R, Kok F. Supplementation with vitamin E but not with β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Arterioscler Thromb 1992;12:554.
47. [47] Baiby AV, Gebicki JM, Sullivan DR. Vitamin E content and low density lipoprotein oxidizability induced by free radicals. Atherosclerosis 1990;81:175.
48. [48] Jessup W, Rankin SM, de Whalley CV, Hoult JRS, Scott J, Leake DS. Alpha-tocopherol consumption during low-density-lipoprotein oxidation. Biochem J 1990;265:399.
49. [49] Reaven P, Parthasarathy S, Beltz W, Witztum J. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992;12:318.
50. [50] Erikson U, Helmius G, Hemmingsson A, Ruhn G, Olsson A. Repeat femoral angiography in hyperlipidemic patients A study of progression and regression of atherosclerosis. Acta Radiol 1988;32:303.
51. [51] Liu K, Cuddy TE, Pierce GN. Oxidative status of lipoproteins in coronary disease patients. Am Heart J 1992;123:285.
52. [52] de Rijke Y, Vogelzang C, van Berkel T, Princen H, Verwey H, van der Laarse A, Bruschke A. Susceptibility of low-density lipoproteins to oxidation in coronary bypass patients. Lancet 1992;340:858.
53. [53] Cominacini L, Garbin U, Pastorino A, Davoli A, Campagnola M, De Santis A, Pasini C, Faccini G, Trevisan M. Bertozzo L, Pasini F, Lo Cascio V. Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 1993;99:63.
54. [54] Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum J. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883.
55. [55] Zieden B, Mölgaard J, Olsson A. Low density lipoprotein oxidation and coronary atherosclerosis. Lancet 1992;340:727.
56. [56] Anderson T, Meredith I, Yeung A, Balz F, Selwyn A, Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium dependent coronary vasomotion. N Engl J Med 1995;332:488.
57. [57] Sasahara M, Raines E, Chait A, Carew T, Steinberg D, Wahl P, Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. Is the extent of atheroclerosis related to the resistance of LDL to oxidation? J Clin Invest 1994;94:55.